{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Hyperthermia as an Adjunct to Immunotherapy in Cancer Treatment"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "Randomisation was conducted using a computer-generated sequence with allocation concealment."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants with resistant tumors were recruited from a single oncology center. Eligibility criteria included patients with advanced-stage cancer unresponsive to standard therapies."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention group received HT combined with immune checkpoint inhibitors (ICIs), while the control group received ICIs alone."
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial aimed to assess the impact of HT on immune response and tumor microenvironment modulation."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the transformation of 'cold' tumors into 'hot' tumors, assessed over a six-month period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was conducted using a computer-generated sequence with allocation concealment."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded to group assignments."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised, with 100 assigned to each group, between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "In the intervention group, 98 participants were analysed using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "demonstrating a significant increase in immune cell infiltration and antigen presentation (mean difference = 5.2, 95% CI 3.1 to 7.3; p = 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were mild, with 3% in the intervention group and 1% in the control group experiencing gastrointestinal side-effects."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678"
      },
      "Funding": {
        "score": 1,
        "evidence": "This trial was funded by the National Cancer Institute."
      }
    },
    "total_score": 23,
    "max_score": 25
  },
  "model": "gpt-4o"
}